股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 寧波健世科技股份有限公司 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09877 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 310,306,209 | RMB | | 1 RMB | | 310,306,209 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 310,306,209 | RMB | | 1 RMB | | 310,306,209 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請 ...

Group 1 - The company reported a total revenue of RMB 25.5 million for the six months ending June 30, 2025, with a primary revenue of RMB 13.4 million and other income of RMB 12.1 million [1] - The adjusted loss for the period was RMB 91.8 million, a decrease of RMB 2.4 million compared to the previous year's loss of RMB 94.2 million, attributed to revenue growth and improved operational efficiency [1] - Research and development expenses increased from RMB 82.2 million in the previous year to RMB 88.9 million during the reporting period, primarily due to a rise in share-based payment expenses from RMB 11.7 million to RMB 36.2 million [1] Group 2 - The company's vision is to become a high-potential medical device enterprise with a global perspective, providing innovative products for the treatment of structural heart diseases [2] - The company plans to accelerate the global business layout and progress of the LuX-Valve product series, aiming to become a benchmark in the transcatheter tricuspid valve replacement field [2] - The company aims to enhance operational efficiency, accelerate revenue and profit growth, and continuously innovate to achieve sustainable development of its long-term international strategy [2]

健世科技-B(09877)发布截至2025年6月30日止六个月的中期业绩，期内实现收入1342.6万元(人民币，下 同)，上年同期未取得收入;毛利1182.7万元，上年同期未取得毛利;研发开支8888.5万元。 公告称，收入主要由于集团的治疗结构性心脏病的介入产品商业化持续推进，销售量增加引起。 2025年上半年，公司在三尖瓣、主动脉瓣、二尖瓣疾病介入治疗领域的产品管线均取得重大进展，形成 了多元化、高潜力产品组合;并且，公司持续加大国际化业务布局力度，提升产品影响力和临床应用规 模，为长期高速增长夯实基础。 ...

Core Viewpoint - The company reported significant revenue growth and advancements in its product pipeline for the treatment of structural heart diseases, indicating a strong foundation for future growth [1]. Financial Performance - The company achieved revenue of 13.426 million RMB for the six months ending June 30, 2025, compared to no revenue in the same period last year [1]. - Gross profit reached 11.827 million RMB, also showing an increase from zero in the previous year [1]. - Research and development expenses amounted to 88.885 million RMB [1]. Product Development - The company made substantial progress in its product pipeline for treating tricuspid, aortic, and mitral valve diseases, resulting in a diversified and high-potential product portfolio [1]. - The commercialization of interventional products for treating structural heart diseases has been a key driver of revenue growth [1]. Strategic Initiatives - The company is intensifying its international business expansion efforts to enhance product influence and clinical application scale, laying a solid foundation for long-term high-speed growth [1].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Jenscare Scientific Co., Ltd. 寧波健世科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：9877） 截至二零二五年六月三十日止六個月的 中期業績公告 董事會欣然宣佈本集團於截至二零二五年六月三十日止六個月的未經審核綜 合 中 期 業 績，連 同 截 至 二 零 二 四 年 六 月 三 十 日 止 六 個 月 的 比 較 數 字 如 下。本 集 團於報告期間的未經審核綜合財務報表已由本公司管理層及審核委員會審閱。 | 財務摘要 | | | | | --- | --- | --- | --- | | | 截至六月三十日止六個月 | | | | | 二零二五年 | 二零二四年 | 同比變動 | | | 人民幣千元 | 人民幣千元 | (%) | | | （未 ...

格隆汇8月15日丨健世科技-B(09877.HK)公告，董事会会议将于2025年8月27日(星期三)举行，藉以(其中 包括)考虑及批准集团截至2025年6月30日止6个月中期业绩及其发布，并考虑建议派发中期股息(如有)， 及处理任何其他事务。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Jenscare Scientific Co., Ltd. 寧波健世科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：9877） 潘斐先生 董事會會議通告 承董事會命 寧波健世科技股份有限公司 執行董事兼首席執行官 寧波健世科技股份有限公司（「本公司」連同其附屬公司「本集團」）董 事（「董 事」） 會（「董事會」）謹 此 宣 佈，董 事 會 會 議 將 於 二 零 二 五 年 八 月 二 十 七 日（星 期 三）舉 行，藉 以（其 中 包 括）考慮及批准本集團截至二零二五年六月三十日止六個月之 中 期 業 績 及 其 發 佈，並 考 慮 建 議 派 發 中 期 股 息（如 有），及 處 理 任 何 其 他 事 務。 香 港，二 零 二 五 年 八 月 十 五 日 於 本 公 告 日 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 寧波健世科技股份有限公司 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09877 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 310,306,209 | RMB | | 1 RMB | | 310,306,209 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 310,306,209 | RMB | | 1 RMB | | 310,306,209 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請 ...

Group 1 - CATL's H-shares reached a new high, closing at HKD 418.20 with a 5.87% increase and a market capitalization of HKD 1.91 trillion, following its successful IPO in May 2023, which raised HKD 35.6572 billion, the largest in Hong Kong this year [1] - Sichuan Baili Tianheng Pharmaceutical's prospectus has automatically lapsed due to not being heard within six months, marking the second time the company has submitted its listing application [2] - KEEP expects a significant reduction in losses for the first half of the year, projecting a loss of approximately HKD 36 million, a 78% decrease year-on-year, with adjusted net profit of about HKD 10 million, attributed to improved business structure and efficiency [3] Group 2 - Jianxi Technology-B announced the successful commercial implantation of its core product, the Ken-Valve, in several hospitals across key provinces, marking a significant milestone in its commercialization process [4] - The Hang Seng Index rose by 0.68% to 24,994.14 points, while the Hang Seng Tech Index increased by 0.84% to 5,585.50 points, and the National Enterprises Index gained 0.60% to 9,040.20 points [5]

Core Insights - Ken-Valve, a transcatheter aortic valve replacement (TAVR) product developed by the company, has successfully completed its first commercial implants in key hospitals across China, marking a significant milestone in its commercialization process [1][2] - The product is designed to treat severe aortic regurgitation or combined aortic stenosis, addressing a critical clinical need in the market for TAVR products [1] - The design features of Ken-Valve, including a one-piece clamping positioning key and an active bending delivery system, enhance valve stability and coaxiality during implantation, catering to patients with complex anatomical structures [1] Market Strategy - The successful launch of Ken-Valve signifies the initiation and smooth advancement of its commercial application in China, prompting the company to expand its sales network and pursue global commercialization of its core products, including the Ken-Valve and LuX-Valve series [2] - The company aims to optimize production costs and operational efficiency to achieve its revenue targets as soon as feasible [2]